Financial Data and Key Metrics Changes - Revenue growth for Q4 2025 was 9%, with adjusted EBITDA net of NCI increasing by 10% and adjusted EPS rising by 20% compared to Q4 2024 [6][12] - For the full year 2025, revenue growth was 10%, adjusted EBITDA net of NCI increased by 15%, and adjusted EPS grew by 31% [6][12] - Net income attributable to UHS per diluted share for Q4 2025 was $7.06, with adjusted net income per diluted share at $5.88 [13][14] Business Line Data and Key Metrics Changes - In the acute care segment, same-facility net revenues increased by 6.9% in Q4 2025, with a 5.4% increase in revenue per adjusted admission [14][15] - The behavioral health segment saw same-facility net revenues increase by 7.2%, supported by a 5.6% increase in revenue per adjusted patient day [17] - Acute care same-facility EBITDA grew by 10.4% in Q4 2025, with EBITDA margin improving to 14.8% [16] Market Data and Key Metrics Changes - Acute care volumes were flat, impacted by softness in the Las Vegas market, but excluding this market, volumes would have increased by 1% [13][14] - Behavioral segment headcount grew by 3.1%, with total same-facility labor expense growth at 7.3% per adjusted day [17][18] Company Strategy and Development Direction - The company is focused on expanding inpatient capacity and enhancing outpatient services, with plans for new service locations and behavioral health projects [8][9] - Technology adoption is a priority, with AI being deployed to improve clinical outcomes and operational efficiency [10][11] - The company aims to sustain its leadership position by diversifying service offerings and payer mix in the behavioral health segment [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing investments in people, facilities, and technology [12] - For 2026, the company expects revenue between $18.4 billion and $18.8 billion, with adjusted EBITDA net of NCI ranging from $2.64 billion to $2.79 billion [19][20] - The guidance includes assumptions about adverse impacts from health insurance exchange reductions and new California staffing regulations [21][22] Other Important Information - Cash generated from operating activities was $1.9 billion for 2025, down from $2.1 billion in 2024, affected by increased receivables and timing of Medicaid payments [18] - The company repurchased 4.65 million shares for $899 million in 2025, with $1.425 billion of repurchase authorization remaining [19] Q&A Session Summary Question: Guidance for 2026 volume growth and pricing assumptions - Management expects a 3%-4% pricing increase in acute care and 2%-3% in behavioral health, acknowledging a moderation in pricing growth [26][27] Question: Impact of AI on operating performance - Initial AI efforts focus on administrative efficiencies, with potential significant impacts on revenue and margins expected over time [28][29] Question: Acute care volume expectations and Nevada market performance - Surgical volume growth in 2025 was positive but lagged overall volume growth; Nevada's market growth was in line with the acute division despite challenges [34][35] Question: Exchange volume visibility and potential bad debt - A 25%-30% decline in exchange volumes is anticipated, with early reporting likely understating the actual decline [39][40] Question: California staffing requirements impact - New staffing regulations will require a different mix of staff, leading to upfront costs and potential short-term volume disruption [45][46] Question: Behavioral outpatient service demand - Outpatient services currently represent about 10% of behavioral segment revenue, with expectations for continued growth in 2026 [51][52] Question: Medicaid supplemental payment programs approval status - Florida's program is expected to be approved soon, while California's program faces more hurdles [70][71]